The complaint alleges that Zoetis violated the Securities Exchange Act by issuing false and misleading statements to shareholders. Central to the dispute is the performance of the company’s flagship products. Specifically, the lawsuit claims that prescription growth for the medication Librela stalled following FDA safety warnings concerning neurological complications in canine patients. Furthermore, the company allegedly lost significant market share across its dermatology and parasite prevention lines, including Trio, Apoquel, and Cytopoint, as new competitors successfully entered the space. Investors who sustained financial losses during this period are encouraged to contact the firm by July 27, 2026, to discuss potential participation in the pending class action. As the case has not yet reached class certification, shareholders currently remain unrepresented and must decide whether to take action or remain absent class members.